Insight
Beyond Clinic
Insight

Information about skin treatments, common questions, and care decisions.

Research Reviews

Masseter Botulinum Toxin: What Changed After Repeat Injection in a Trial?

Written by Beyond Clinic editorial team · Medically reviewed by Hyojung Moon, MD · Published

In a 180-person phase 3 trial of benign masseteric hypertrophy, the adjusted difference in masseter thickness between prabotulinumtoxinA and placebo was greatest at 12 weeks and narrowed through week 24. Measured from the injection date, the trial’s median time to meet its combined grade and ultrasound thresholds again after 12 weeks was 20.14 weeks; this was not a personal duration estimate or retreatment interval. The 12-week change after retreatment was not statistically different from the change after the first injection (p = .6279). Only one dose was tested, the extension was open-label, follow-up stopped at 48 weeks, and two of ten authors were employed by the studied drug’s manufacturer.

  • In the 24-week double-blind, placebo-controlled core phase, 90 people were assigned to each group. Of these, 114 again met the criteria and consented to a 24-week open-label extension; all received the studied drug.
  • Participants received 48 U total, 24 U in each masseter. This is the studied regimen, not a dose recommendation.
  • At maximum clenching, the adjusted between-group difference in change from baseline was −1.96 ± 0.16 mm at week 4, −2.85 ± 0.19 mm at week 8, and −2.89 ± 0.20 mm at week 12; it then narrowed through week 24.
  • The 20.14-week median (95% CI 19.00–21.14) was measured from the injection date to meeting the combined grade-and-thickness criteria again after 12 weeks.
  • Changes 12 weeks after first and repeat treatment were −3.43 ± 1.27 mm and −3.22 ± 1.73 mm (p = .6279). These are the main-text values; Table S5 reverses the first/repeat assignments, and which is correct remains unresolved. A nonsignificant difference is not proof of equal responses.
  • Treatment-emergent events, drug-related reactions, and findings from the small cone-beam CT subgroup have different denominators. Zero reported serious events cannot establish long-term safety.

Seok and colleagues enrolled people with symmetric benign masseteric hypertrophy. They tested prabotulinumtoxinA (PRA; studied as NABOTA, manufactured by Daewoong Pharmaceutical). The brand names the trial drug. The findings belong to this study’s participants and protocol, without describing a clinic’s results or comparing botulinum toxin products.

Key findings

The core study randomized 180 participants 1:1 to PRA 48 U or saline placebo for 24 weeks. At week 24, 114 people again met entry criteria and agreed to continue. They entered an open-label extension and received PRA regardless of their first assignment: 48 had received PRA and 66 had received placebo. Later comparisons therefore lacked a blinded placebo group.

Ultrasound measured masseter thickness during maximum clenching. The least-squares mean between-group difference in change from baseline (PRA minus placebo, ± standard error) was −1.96 ± 0.16 mm at week 4, −2.85 ± 0.19 mm at week 8, and −2.89 ± 0.20 mm at week 12. The paper reports p < .0001 at every core assessment. The difference peaked at week 12, then narrowed through week 24. Three-dimensional lower-face volume had its largest between-group difference at week 12 too, although Methods says maximum clenching and Results says rest for its measurement position.

The authors called 20.14 weeks (95% confidence interval [CI] 19.00–21.14) a median maintenance duration. Its clock started on the injection date. The event required a return after 12 weeks to a Masseter Muscle Hypertrophy Scale (MMHS) grade of at least 4 and bilateral maximum-clenching thickness of at least 14 mm in men or 12 mm in women. That definition does not set a repeat-injection schedule. Satisfaction meant a score of 6 or 7 on a 1-to-7 scale; the proportions differed between groups at every core assessment (all p < .0001).

At 12 weeks after each administration, mean thickness change was −3.43 ± 1.27 mm after the first injection and −3.22 ± 1.73 mm after retreatment (p = .6279). These are the main-text values; Table S5 reverses the first/repeat assignments, and which is correct remains unresolved. The trial detected no statistically significant difference. This finding cannot show that one person’s response will remain the same after further injections.

For safety analysis, one participant assigned to placebo received PRA, yielding 91 in the PRA group and 89 in the placebo group. In the core phase, treatment-emergent adverse events occurred in 13.19% and 22.47%, respectively; the numerically higher placebo figure did not establish a statistically significant safety difference. Drug-related reactions occurred in 5.49% and 2.25%, respectively. The paper describes these related events as mild. In the full core-plus-extension period after first PRA exposure, treatment-emergent events were reported in 27.08% of the PRA–PRA group and 15.15% of the placebo–PRA group; drug-related reactions were 6.25% and 7.58%. Reported reactions included mastication disorder, injection-site reaction or pain, and headache. No serious adverse event was reported. These denominators and observation periods differ and should not be pooled into a single risk estimate.

Author affiliations and disclosures

No explicit funding or conflict-of-interest declaration was found in the reviewed final-version main text. The early-publication reproduction reports Daewoong’s funding and trial-drug supply and the authors’ declaration of no significant interests involving commercial supporters. This is an author self-report, not independent verification; whether the final version contains the same declaration remains unverified. PubMed and Crossref affiliation metadata in the source analysis identify Yun SH and Kim DH, two of the ten authors, as employees of Daewoong Pharmaceutical, which made the studied drug. Their affiliations do not establish who funded the trial or their individual financial interests.

Why this question matters

The paper concerns enlargement of both masseter muscles. Its Introduction describes earlier surgical approaches, including mandibular or masseter resection and subcutaneous liposuction, before botulinum toxin injection. The trial did not compare or rank those options for individuals.

The authors said standardized treatment guidance was lacking. To their knowledge, this was the first phase 3 study to examine effectiveness, duration, and adverse events through 48 weeks. That claim reflects their reading of the literature; it has not been independently verified against every study.

What the trial measured

The 24-week core phase was multicenter, randomized, double-blind, and placebo-controlled at two Korean hospitals. The intervention was a single 48 U regimen, divided as 24 U per masseter. The trial assessed ultrasound thickness at maximum clenching and at rest, three-dimensional lower-face volume, a 1-to-5-point MMHS grade, and satisfaction on a 1-to-7-point scale. Only volunteers underwent cone-beam computed tomography (CBCT) for mandibular bone measures: 60 in the core phase and 38 in the extension.

The trial excluded people who had received botulinum toxin in the preceding 3 months, had lower-face-contour surgery in the preceding 12 months, or had potentially confounding conditions. The paper does not describe those conditions in detail. These exclusions limit what the safety findings can say; they are not universal contraindications.

The investigators did not measure an onset before week 4. In the core phase, the adjusted thickness differences at weeks 4, 8, and 12 were −1.96 ± 0.16, −2.85 ± 0.19, and −2.89 ± 0.20 mm. The three-dimensional volume measure also differed between groups at all measured core time points (all p < .0001), with the largest difference at week 12, but the Methods and Results use conflicting descriptions of rest versus maximum clenching for that volume assessment.

The 20.14-week median is tied to the MMHS grade and sex-specific ultrasound thresholds above. It does not measure how long every visible contour change lasted. The 6-to-7-point satisfaction definition and its core-phase between-group findings are separate subjective outcomes. The open-label retreatment comparison occurred after eligibility screening and consent at week 24, so it cannot be read as a continuing placebo-controlled test.

Core drug-related reactions comprised five mastication-disorder events and one injection-site reaction in the PRA safety group, versus one mastication-disorder event and one injection-site pain event in the placebo safety group. In the extension, the PRA–PRA group had three mastication-disorder events and one injection-site pain event; the placebo–PRA group had three mastication-disorder events, two injection-site pain events, and one headache event. The reported mastication disorders were mild. Seek immediate medical evaluation for severe or persistent chewing difficulty; do not try to judge it yourself or wait.

Voluntary CBCT analysis included 28 PRA and 32 placebo participants in the core phase, and 16 PRA–PRA and 22 placebo–PRA participants in the extension. The investigators reported no statistically significant changes in bigonial width, gonial angle, or mandibular body length in that subgroup. A small self-selected subgroup observed for at most 48 weeks cannot settle cumulative bone safety.

Four ways to read the paper

Historical context

The authors describe botulinum toxin injection as a nonsurgical option that followed older surgical methods for masseteric hypertrophy. This background does not show one method is preferable to another.

Strength and limits of the design

Randomization and blinding support the placebo comparison during the initial 24 weeks. The trial tested one 48 U regimen at two Korean centers. After week 24, participants again had to qualify and consent; everyone in the extension received PRA. The voluntary CBCT subgroup was smaller.

Clinical meaning of retreatment and bone findings

The repeat-injection comparison found no statistically detectable difference in 12-week thickness change. The authors noted earlier reports suggesting that repeated botulinum toxin exposure may affect bone, although their CBCT subset showed no significant mandibular change. They advised against exceeding recommended doses while the bone question remains open. The paper also says the effect of injections into masticatory muscles on the temporomandibular joint is unknown. These are study interpretations and uncertainties, not a personal dosing plan.

What to communicate to a patient

The week-12 maximum, 20.14-week median, and retreatment comparison answer separate questions. They cannot predict an individual’s response, set an injection date, or establish a clinic result. The manufacturer’s author affiliations and the early-publication funding and author declaration remain part of the study’s context; the final-version wording is unverified.

What can be taken from the results

The placebo-adjusted thickness difference peaked at week 12 and narrowed through week 24. Median return to the combined grade-and-thickness event was 20.14 weeks. The 12-week changes after first and repeat treatment did not differ significantly. Each finding is limited by the studied dose, entry criteria, two-center sample, and 48-week observation window. An individual’s past course and functional symptoms need clinical assessment.

Limits to keep in view

  • The study tested one dose, 48 U total and 24 U per side. It did not compare other doses, injection points, dilution, or intervals.
  • Enrollment occurred at two Korean centers. The available article has no race or ethnicity table, so it cannot establish a single-ethnicity sample or be generalized without care to other populations.
  • The 24-week extension selected participants who again met criteria and consented, and it was open-label without continuing placebo control.
  • CBCT was voluntary; 60 core and 38 extension participants were analyzed. Selection and limited power constrain the bone finding.
  • Follow-up ended at 48 weeks. Later repeated dosing, cumulative risks, and bone changes were not assessed.
  • The Methods and Results disagree on whether three-dimensional lower-face volume was measured at maximum clenching or rest.
  • No explicit funding or conflict-of-interest declaration was found in the reviewed final-version main text. The early-publication reproduction reports Daewoong’s funding and trial-drug supply and the authors’ declaration of no significant interests involving commercial supporters. This is an author self-report, not independent verification; whether the final version contains the same declaration remains unverified. Two of ten authors were affiliated with the drug manufacturer in recorded metadata.

References

  1. Seok J, Koh YG, Hong JK, Yun SH, Kim DH, Son HS, Choi SY, Yoo KH, Lee YW, Kim BJ. “Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.” Dermatologic Surgery. 2024;50(6):527–533. PubMed · DOI

Frequently asked questions

When did the trial first detect a change in masseter thickness?
The first assessment was at 4 weeks. At maximum clenching, the adjusted between-group difference in change from baseline was −1.96 ± 0.16 mm at 4 weeks and reached its largest reported value, −2.89 ± 0.20 mm, at 12 weeks. The trial did not measure an earlier onset.

Was the change after repeat injection different?
At 12 weeks after first and repeat injections, the reported thickness changes were −3.43 ± 1.27 mm and −3.22 ± 1.73 mm, respectively (p = .6279). These are the main-text values; Table S5 reverses the first/repeat assignments, and which is correct remains unresolved. This comparison did not detect a statistically significant difference. It does not prove identical responses for an individual or over further injections.

Does the reported 20.14 weeks set a repeat-injection interval?
No. The median was 20.14 weeks (95% CI 19.00–21.14) under this trial's event definition: from the injection date to meeting both its masseter grade and sex-specific ultrasound-thickness criteria again after 12 weeks. It is not a personal duration forecast or a standard retreatment schedule.

What adverse events were reported?
Drug-related events included mastication disorder, injection-site reaction or pain, and headache; the paper describes related mastication disorders as mild. No serious adverse event was reported through 48 weeks. The small voluntary cone-beam CT subgroup and limited follow-up cannot establish long-term safety. Seek immediate medical evaluation for severe or persistent chewing difficulty; do not try to judge it yourself or wait.

How should someone use this trial for an individual decision?
It cannot set a person's dose or retreatment date. Discuss current symptoms, the course after any earlier injection, and unusual functional problems with a clinician. This review cannot determine whether the product is authorized in a given country or whether an individual should start, change, or stop using it.

Read the Korean original

Questions about your care

Discuss questions about your care with our clinical team.

Once you verify your identity using a passport issued outside Korea, you can book without a Korean phone number. If you have trouble booking, message us on WhatsApp.

Beyond Clinic

Address
6th Floor, JY Building, 826 Nonhyeon-ro, Gangnam-gu, Seoul, South Korea
Contact
+82-2-6408-2080 · +82-2-6408-2081
Business Hours
Mondays and Fridays · 10:00 a.m.–8:00 p.m. · Last appointment at 7:00 p.m.Tuesdays and Thursdays · 10:00 a.m.–7:00 p.m. · Last appointment at 6:00 p.m.Saturdays · 10:00 a.m.–4:00 p.m. · Last appointment at 3:00 p.m.Lunch break: 2:00–3:00 p.m. (no lunch break on Saturdays)Closed Wednesdays, Sundays, and public holidays.